BOXIONG TANG, Executive Director, Health Economics and, Outcomes Research (HEOR), BeiGene

•   Dr. Tang has over 23 years experiences in medicine, public health, and health economics and outcomes research.

•   Currently, he is the Executive Director, Head ofHealth Economics and Outcomes Research (HEOR) at Beigeneex-China Medical Affairs, responsible for developing HEOR function and implementing health outcomes researchstrategies globally. He established HEOR function to support the product launches and reimbursement globally.

•   Before joining Beigene, he served as a Sr. Director of Global HEOR, and Growth Markets at Teva Pharmaceutical. Dr. Tang has established the newly created Growth Markets Market Access and HEOR team within Teva.

•   Previous, Dr. Tang was a Senior Director of Health Outcomes Research at Pfizer Emerging Markets supporting Asia region. His responsibilities includes developing and implementing research strategies in clinical development (specialized in health economics assessment and patient reported outcomes, product value dossiers), and post market products (real world and large database creation and analysis). Dr. Tang is specialized in therapeutic areas of oncology, hematology, and immunology (biologics), and women’s health.

•   Prior to Pfizer, Dr. Tang was the director of Health Economics and Clinical Outcomes Research in Johnson & Johnson and GlaxoSmithKline, where he was responsible for health outcomes research in biologics and oncology.

•   He was also an adjuvant professor of China Fudan University and faculty of Zhejiang University Medical School. Meanwhile, Dr. Tang was the Chair of the HTA (Industry) Committee, Asia Consortium of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and a member of Asia Consortium Executive Committee.

•   Dr. Tang’s training includes a MD in Preventive Medicine, a PhD in Health Services Research, and a MPH in Health Planning and International Health.

•   Dr. Tang serves as the chair of Industry Committee of International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Asia Consortium. He has published more than 30 manuscripts in peer review journals, 100+ abstracts and numerous speeches and presentations in major scientific congresses including ISPOR. He is knowledgeable in the development of Health Technology Assessment around the world. In addition, he served at Scientific Committees of International Health Economics Association (iHEA),Society for Medical Decision Making (SMDM), and a Peer Reviewer of America Journal of Managed Care.